Dr Martin Kaiser

Consultant Haematologist MD, RWTH (Aachen University, Germany)

Specialism: Haemato-oncology

Available at: Sutton

Special interests:

  • myeloma


Dr Martin Kaiser has both a private and an NHS practice at The Royal Marsden. Dr Martin Kaiser is a Consultant Haematologist at The Royal Marsden and a Clinician Scientist at The Institute of Cancer Research. After graduating from medical school at RWTH University Aachen, Germany, he obtained an MD degree at the same university through a myeloma research project. He completed his medical and his haematology specialist training at Charité University Hospital in Berlin, Germany. Throughout his training he undertook translational research in the field of myeloma, lymphoma and acute leukaemia. His interest in the genetics and epigenetics of myeloma led him to join the Centre for Myeloma Research at The Institute of Cancer Research.

Martin is a dedicated haemato-oncologist and combines his clinical work with laboratory-based research. He is an expert the clinical management of multiple myeloma and associated plasma cell dyscrasias such as MGUS and amyloidosis. He is involved in several phase I, II and III clinical studies that investigate novel treatment approaches for myeloma. As a clinician scientist he is keen to understand the biologic principles of myeloma through laboratory research with a focus on translating the findings into diagnostic and therapeutic tools to improve the treatment of patients. 

He is involved in developing innovative molecular diagnostic tests which help identify patient subgroups of myeloma that are candidates for specific treatments. His research regarding the epigenetic features of myeloma aims at identifying potential novel epigenetic therapeutic targets.

Martin has authored numerous research articles in peer-reviewed journals and has been a speaker at national and international conferences. He is involved in tissue biobanking at the ICR for the Myeloma UK trial network as well as for the Myeloma XI trial, one of the largest myeloma trials ever conducted.

Clinical units